[EFFECT] Tharimmune, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

07/10/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	July 9, 2025 5:00 P.M.

Form:

S-3

CIK:	0001861657
Company Name:	Tharimmune, Inc.
File Number:	333-288518

Source: View Original Filing on SEC EDGAR

Tharimmune Inc

NASDAQ:THAR

THAR Rankings

#5055 Ranked by Market Cap

N/A Ranked by Dividends

THAR Latest News

Nov 13, 2025

Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Nov 6, 2025

Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

Nov 3, 2025

Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

Aug 20, 2025

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Aug 13, 2025

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

THAR Latest SEC Filings

Nov 14, 2025

[Form 3] Tharimmune, Inc. Initial Statement of Beneficial Ownership

Nov 14, 2025

[Form 3] Tharimmune, Inc. Initial Statement of Beneficial Ownership

Nov 10, 2025

[8-K] Tharimmune, Inc. Reports Material Event

Nov 6, 2025

[424B5] Tharimmune, Inc. Prospectus Supplement (Debt Securities)

Nov 6, 2025

[8-K] Tharimmune, Inc. Reports Material Event

THAR Stock Data

Market Cap 89.71M

Float 32.47M

Insiders Ownership 17.13%

Institutions Ownership 1.5%

Short Percent 12.08%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City BRIDGEWATER